| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9724310 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(4 years from now) | |
| US8231906 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9730900 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(4 years from now) | |
| US9833419 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(4 years from now) | |
Minivelle is owned by Noven.
Minivelle contains Estradiol.
Minivelle has a total of 4 drug patents out of which 0 drug patents have expired.
Minivelle was authorised for market use on 29 October, 2012.
Minivelle is available in film, extended release;transdermal dosage forms.
Minivelle can be used as a method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent no. 9730900.
The generics of Minivelle are possible to be released after 04 July, 2030.
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 October, 2012
Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent ...
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
MINIVELLE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic